Form 4: Madrigal Pharmaceuticals Director Exercises Options and Sells Shares Under Pre-Arranged Plan

Madrigal Pharmaceuticals Director Rebecca Taub executed a planned transaction, exercising stock options and simultaneously selling an equal number of common shares.

Summary

• Director Rebecca Taub acquired 1,000 shares of Madrigal Pharmaceuticals, Inc. common stock by exercising stock options at a price of $9.45 per share on July 18, 2025.
• On the same date, July 18, 2025, Ms. Taub disposed of 1,000 shares of common stock at a weighted average price of $350.005 per share, with prices ranging from $350.00 to $350.05.
• The sale was conducted pursuant to a Rule 10b5-1 trading plan, which was adopted by Ms. Taub on March 14, 2025.
• Following these transactions, Ms. Taub directly beneficially owns 461,044 shares of common stock and indirectly owns 655,540 shares through SQN LLC.
• Ms. Taub also holds 46,463 stock options, which are fully vested and exercisable, with an expiration date of July 22, 2026.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While there is an insider sale, it was conducted under a pre-arranged 10b5-1 plan, which mitigates the negative signal often associated with insider selling. The exercise of options also indicates a realization of value.

Positives

• The exercise of stock options at a low price ($9.45) indicates a historical benefit to the director.
• The sale of shares at a significantly higher price ($350.005) demonstrates the director's ability to realize substantial gains from her equity holdings.

Negatives

• The sale of shares by a director, even under a pre-arranged plan, represents a reduction in insider ownership, which some investors may interpret as a less positive signal.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic outlook, as it is solely a report of insider trading activity.

Industry Context

Insider transactions, such as those reported on Form 4, are routine disclosures in the U.S. equity markets. The use of a Rule 10b5-1 trading plan is a common practice among corporate insiders to pre-arrange stock sales, providing an affirmative defense against insider trading allegations and indicating that the transaction was not based on material non-public information.

Related Party Transactions

• Rebecca Taub indirectly owns 655,540 shares through SQN LLC, where she and her spouse are managing members. She disclaims beneficial ownership of these securities except to the extent of her pecuniary interest.

Stakeholder Impact

• Shareholders may note the director's sale of shares, although the pre-arranged nature of the transaction under a 10b5-1 plan typically reduces concerns about its signaling effect.

Key Dates

Keywords

Madrigal Pharmaceuticals, MDGL, Form 4, Insider Trading, Stock Option Exercise, Stock Sale, Rebecca Taub, 10b5-1 Plan, Director